Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Nasdaq Real Time Price USD

Vericel Corporation (VCEL)

39.42
-1.45
(-3.55%)
At close: April 22 at 4:00:01 PM EDT
40.40
+0.98
+(2.49%)
Pre-Market: 4:31:53 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
237,224
237,224
197,516
164,365
156,184
Cost of Revenue
65,117
65,117
61,940
54,577
50,159
Gross Profit
172,107
172,107
135,576
109,788
106,025
Operating Expense
167,588
167,588
142,040
126,846
113,879
Operating Income
4,519
4,519
-6,464
-17,058
-7,854
Net Non Operating Interest Income Expense
5,796
5,796
4,032
975
220
Other Income Expense
195
195
64
95
52
Pretax Income
10,510
10,510
-2,368
-15,988
-7,582
Tax Provision
148
148
814
721
-111
Net Income Common Stockholders
10,362
10,362
-3,182
-16,709
-7,471
Diluted NI Available to Com Stockholders
10,362
10,362
-3,182
-16,709
-7,471
Basic EPS
0.08
0.21
-0.07
-0.35
-0.16
Diluted EPS
0.08
0.20
-0.07
-0.35
-0.16
Basic Average Shares
48,416.50
48,848
47,590
47,130
46,472
Diluted Average Shares
48,416.50
51,679
47,590
47,130
46,472
Total Operating Income as Reported
4,519
4,519
-6,464
-17,058
-7,854
Total Expenses
232,705
232,705
203,980
181,423
164,038
Net Income from Continuing & Discontinued Operation
10,362
10,362
-3,182
-16,709
-7,471
Normalized Income
10,362
10,362
-3,182
-16,709
-7,471
Interest Income
6,410
6,410
4,632
1,341
224
Interest Expense
614
614
600
366
4
Net Interest Income
5,796
5,796
4,032
975
220
EBIT
11,124
11,124
-1,768
-15,622
-7,578
EBITDA
16,628
16,628
2,864
-11,641
-4,613
Reconciled Cost of Revenue
65,117
65,117
61,940
54,577
50,159
Reconciled Depreciation
5,504
5,504
4,632
3,981
2,965
Net Income from Continuing Operation Net Minority Interest
10,362
10,362
-3,182
-16,709
-7,471
Normalized EBITDA
16,628
16,628
2,864
-11,641
-4,613
Tax Rate for Calcs
0
0
0
0
0
12/31/2021 - 2/4/1997

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MSB.AX Mesoblast Limited
1.7000
+5.59%
 
MDWD MediWound Ltd.
17.95
+1.70%
 
MESO Mesoblast Limited
10.86
+5.64%
 
MRUS Merus N.V.
43.21
-0.05%
 
ZYME Zymeworks Inc.
12.16
+3.49%
 
KRYS Krystal Biotech, Inc.
168.80
+4.26%
 
CNTA Centessa Pharmaceuticals plc
12.67
+4.28%
 
MREO Mereo BioPharma Group plc
2.5000
+7.30%
 
CDTX Cidara Therapeutics, Inc.
21.98
+6.26%
 
TVTX Travere Therapeutics, Inc.
15.88
+5.10%